Proteome Biochip Autoantibody Profiling for TBI Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic systems are inadequate for accurately diagnosing and tracking the onset and progression of traumatic brain injury (TBI) and associated neurodegenerative diseases such as chronic traumatic encephalopathy, Alzheimer's disease, and Parkinson's disease, particularly for mild to moderate TBIs, which are under-diagnosed and lack reliable methods to predict neurodegenerative progression.
Innovation Solution
A systems biology-based whole brain proteome biochip platform that utilizes microarrays to detect and measure autoimmune response biomarker panels by printing brain protein fractions into micro-wells, allowing for the detection of autoantibodies in biological samples to diagnose and track TBI and associated neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic systems are used, then diagnosis can be performed, but accuracy and reliability for tracking TBI progression and predicting neurodegenerative disease are insufficient
Solution Approach 1:
The diagnostic system segments the complex TBI diagnosis into multiple biomarker panels (acute phase proteins, neurodegenerative markers, immune response markers) measured at different time points. This segmentation allows targeted detection of specific disease stages and mechanisms, improving both reliability and precision by focusing on clinically relevant parameters rather than attempting to measure everything simultaneously.
Solution Approach 2:
The system performs preliminary diagnostic actions by establishing baseline biomarker levels at the time of TBI occurrence, then uses these baselines to detect deviations indicating progression to neurodegenerative disease. This preliminary measurement approach enables early detection and tracking before severe symptoms manifest, significantly improving diagnostic reliability and measurement precision.
2Measurement precision
If comprehensive biomarker panels are measured, then diagnostic accuracy improves, but test complexity and cost increase
Solution Approach 1:
The comprehensive diagnostic panel is segmented into distinct biomarker categories (acute phase proteins like S100B and GFAP, neurodegenerative markers like tau and alpha-synuclein, immune response markers). Each category can be measured independently at different time points, allowing the test complexity to be managed through modular assessment rather than requiring all markers to be measured simultaneously in a single complex test.
Solution Approach 2:
The diagnostic approach is dynamic, adapting the biomarker panel composition based on the clinical stage and specific diagnostic question. Acute phase proteins are prioritized in the immediate post-injury period, while neurodegenerative markers become more relevant at later stages. This dynamic adjustment optimizes diagnostic accuracy while managing test complexity by measuring only the most relevant markers at each time point.
3Measurement precision
If repeated TBI assessments are performed to track progression, then monitoring accuracy improves, but time loss and resource consumption increase
Solution Approach 1:
The system establishes baseline biomarker measurements at the time of TBI occurrence, which serves as a reference for future comparisons. This preliminary action enables efficient longitudinal tracking by providing a clear baseline against which to measure progression, reducing the time needed for repeated assessments and improving accuracy through consistent reference points.
Solution Approach 2:
The diagnostic system incorporates feedback mechanisms by comparing current biomarker levels against baseline values and established diagnostic criteria. This feedback approach enables rapid identification of progression patterns, allowing clinicians to make informed decisions about further monitoring or intervention without requiring excessive repeated measurements, thus improving accuracy while minimizing time loss.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a fast, inexpensive, and reliable point-of-care diagnostic system capable of identifying TBI and associated neurodegenerative disease progression through the detection of autoantibodies, facilitating early intervention and therapy development.
Implementation Method 1
The proteome biochip is helpful in determining the details of a traumatic brain injury. A biological sample from a patient is then applied to the biochip. By determining binding of sample proteins from the patient, the nature of the traumatic brain injury is diagnosed.
Data Source
AI summary
A system and method for diagnosing traumatic brain injury (TBI) includes a proteome biochip including a set of brain protein fractions including primary serum autoantibodies reactive with brain protein autoantigens released by the TBI printed into micro-wells of a glass slide. The biochip hybridized with non-TBI and TBI-injured serum samples from which an autoantibody response profile is generated. The system additionally including labeled IgG or IgM secondary antibodies for addition to the micro-wells for binding with one of the primary serum autoantibodies, a side illumination laser to read the micro-wells in which the labeled IgG or IgM secondary antibodies are bound with one of the primary serum autoantibodies, and a readout detection system for the set of brain protein fractions to screen for autoantigens present in the micro-wells that contain the labeled IgG or IgM secondary antibodies bound with one of the primary serum autoantibodies to generate a heat map.